Harnessing the Therapeutic Power of the Mitochondria

Our company is a first-mover and leader in exploring the mitochondrial genome for therapeutically relevant peptides that have the potential to be developed into transformative and commercially successful drugs. Our lead program, CB4211, in development for NASH and obesity and is expected to enter clinical trials in mid-2018. To date, our founders and scientists have discovered more than 100 biologically active mitochondrial peptides.

Proprietary Technology Platform

Our proprietary technology platform is designed to rapidly identify previously unexplored peptides encoded within the mitochondrial genome, characterize their biological activity, and optimize them into novel therapeutics.

Lead Candidate Targets NASH and Obesity

Our lead MBT drug candidate, CB4211, is a novel, optimized analog of MOTS-c, a naturally occurring mitochondrial peptide discovered by our founder, Dr. Pinchas Cohen and his academic collaborator, whose research has shown that MOTS-c plays a significant role in the regulation of metabolism. CB4211 is being developed to potentially treat NASH and obesity.